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Conclusion: A single high loading dose of atorvastatin administered
#24 hours before contrast media (CM) exposure reduces the rate of
contrast-induced acute kidney injury (CIAKI). The beneﬁt is only seen in
patients at low to medium risk.
Summary: After the administration of intravenous contrast CIAKI
occurs in <1% to >50% of patients, depending on risk factors and
the patient population studied (McCullough PA, J Am Coll Cardiol
2008;51:1419-28). CM is felt to introduce harmful hemodynamic changes
in renal blood ﬂow, leading to hypoxia of the renal medulla and direct toxic
effects on renal cells (Tumlin J et al, Am J Cardiol 2006;98:14-20K). CM
may also induce apoptotic cell death. Among the pleiotropic effects of statins
are their effects on the apoptotic pathway. In the present study, the authors
investigated the effects of atorvastatin pretreatment on CIAKI and the effects
of atorvastatin pretreatment on CM-mediated modiﬁcations of intercellular
pathways leading to apoptosis or survival of renal tubular cells. The authors
ﬁrst investigated the in vivo effects of atorvastatin on CIAKI in patients
with chronic kidney disease enrolled in the Novel Approaches for Preventing
or Limiting Events (NAPLES) II trial. Patients were randomly assigned to an
atorvastatin group (80 mg #24 hours before CM exposure; n ¼ 202) or to
the control group (n¼ 208). All patients received a high dose of N-acetylcys-
teine and sodium bicarbonate solution. Second, the authors investigated
the in vitro effects of atorvastatin pretreatment on CM-mediated modiﬁca-
tions of intercellular pathways potentially leading to apoptosis or survival of
renal tubular cells. CIAKI, deﬁned as an increase of 10% of serum cystatin
C concentration #24 hours of CM exposure, occurred in 9 of 202 patients
(4.5%) in the atorvastatin group and in 37 of 208 patients (17.8%) in the
control group (odds ratio, 0.22; 95% conﬁdence interval, 0.70-0.69;
P ¼ .005). The CIAKI rate was lower in the atorvastatin group in diabetic
and nondiabetic patients and in patients withmoderate chronic kidney disease
(estimated glomerular ﬁltration rate, 31-60 mg/min/1.73 m2). In the in
vitro model, pretreatment with atorvastatin, prevented CM-induced renal
cell apoptosis and restored survival signals mediated by protein kinase
B (AKT) and extracellular signal-regulated kinase (ERK) pathways.
Comment: The concept of adding a single high loading dose of ator-
vastatin before CM exposure to prevent CIAKI is attractive. The treatment
is easy to do and likely very safe. This study suggests still another pleiotropic
effect of statin medications, but it appears to be conﬁned only to patients at
low to medium risk of CIAKI.Randomized Clinical Trial of Endovenous Laser Ablation Versus
Conventional Surgery for Small Saphenous Varicose Veins
Samuel N, Carradice D, Wallace T, et al. Ann Surg 2012;00:1-8.
Conclusion: Endovenous laser ablation (EVLA) and conventional
surgery produce similar improvements in the venous clinical severity scores
and quality of life in the treatment of small saphenous varicose veins. EVLA
has less periprocedural morbidity, providing faster recovery.
Summary: About 15% of patients with symptomatic varicose veins
have isolated saphenopopliteal junction incompetence associated with small
saphenous vein reﬂux (Engelhorn CA et al, J Vasc Surg 2005;41:645-51).
Open surgical treatment of saphenopopliteal junction reﬂux has been the
accepted gold standard treatment of small saphenous vein incompetence.
However, surgical exploration of the saphenopopliteal junction is
considered more technically challenging than that of the saphenofemoral
junction. There is a lack of consensus on treatment for saphenopopliteal
junction incompetence (Winterborn RJ et al, Eur J Vasc Endovasc Surg
2004;28:400-3). Endovenous procedures have advantages over open
striping procedures for treatment of great saphenous vein incompetence
with respect to perioperative morbidity. There have been a number of
randomized trials in which endovenous ablation techniques have been
compared with greater saphenous vein stripping but no such trials for the
treatment of saphenopopliteal incompetence. In this particular trial the
so-called gold standard of conventional surgery for saphenopopliteal
junction incompetence was compared with EVLA in the management
of small saphenous vein incompetence. Patients with unilateral primary892saphenopopliteal junction incompetence and small saphenous vein reﬂux
were randomized equally in parallel groups receiving EVLA or surgery.
Patients were assessed at baseline and at 1, 6, 12, and 52 weeks. Outcomes
included successful ablation of axial reﬂux on duplex imaging, visual analog
pain scores, recovery times, complication rates, venous clinical severity
scores, and quality of life proﬁling. A total of 106 patients were recruited
and randomized to surgery (n ¼ 53) or EVLA (n ¼ 53). EVLA resulted
in a higher ablation of short saphenous vein reﬂux than surgery (96.2% vs
71.7%; P < .001). Postoperative pain was lower after EVLA (P < .05).
Patients returned to work earlier after EVLA, with quicker return to normal
function (P < .001). The incidence of minor sensory disturbances was
26.4% with surgery vs 7.5% in the EVLA group (P ¼ .009). There were
similar improvements in venous clinical severity scores and measures of
quality of life.
Comment: The data very much mirror randomized data for the
comparison of stripping of the great saphenous vein vs endovenous ablation
techniques. Longer-term outcomes are similar but, with less pain and faster
recovery using the EVLA techniques. The data here are only presented out
to 1 year. Because EVLA seems to be more effective in addressing the
underlying pathophysiology of small saphenous vein incompetence, even
longer-term data will be needed to ultimately determine whether recurrence
rates with EVLA for small saphenous insufﬁciency will, in fact, be lower than
with open surgery.Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism
Brighton TA, Eikelboom JW, Mann K, and the ASPIRE Investigators.
N Engl J Med 2012;367:1979-87.
Conclusion: Aspirin did not reduce the rate of recurrence of venous
thromboembolism after a ﬁrst episode of unprovoked venous
thromboembolism.
Summary: It is well known that after an episode of unprovoked
venous thromboembolism (VTE), patients are at signiﬁcant risk for recur-
rent VTE after discontinuation of anticoagulation therapy. Long-term treat-
ment with vitamin K antagonists reduces the risk of recurrent VTE but does
not improve survival and is associated with increased risk for bleeding. Low-
dose aspirin is inexpensive and simple to administer and clearly effective in
the prevention of arterial vascular events. It has been used as primary
prevention of VTE in high-risk surgical patients (Antiplatelet Trialists’
Collaboration, BMJ 2002;324:71-86). It has also been suggested that
aspirin may be effective in preventing recurrence of VTE after an initial
event (Becattini C et al, N Engl J Med 2012;366:1959-67). The authors
of this study randomly assigned 822 patients who had completed initial anti-
coagulation therapy after a ﬁrst episode of unprovoked VTE to receive
aspirin at a dose of 100 mg/d or placebo for up to 4 years. Primary outcome
was recurrence of VTE. During the median follow-up of 37.2 months, VTE
recurred in 73 of 411 patients treated with placebo and in 57 of 411
assigned to aspirin (6.5% per year for placebo vs 4.8% per year for aspirin;
hazard risk [HR] with aspirin, 0.74; 95% conﬁdence interval [CI],
0.25-1.05; P ¼ .09). Aspirin reduced the rate of two prespeciﬁed secondary
composite outcomes. The rate of VTE, myocardial infarction, stroke, or
cardiovascular death was reduced by 34% (8% per year for placebo vs
5.2% per year with aspirin; HR with aspirin, 0.66; 95% CI, 0.48-0.92;
P ¼ .01). The rate of VTE, myocardial infarction, stroke, major bleeding,
or death from any cause was reduced by 33% (HR 0.67; 95% CI,
0.49-0.91; P ¼ .01). There were no differences in the rates of major or clin-
ically relevant nonmajor bleeding episodes (0.6% per year for placebo vs
1.1% per year for aspirin; P ¼ .22).
Comment: The authors point out that the ASPIRE trial was not
sufﬁciently powered to show a signiﬁcant reduction in the primary end
point of recurrent VTE. Their data when combined, as prospectively
planned, with the WARFASA Study (Becattini C et al, N Engl J Med
2012;366:1959-67) did show a clear aspirin effect. Combined results of
the WARFASA and the ASPIRE trial show a highly signiﬁcant reduction
of 32% in recurrent VTE (P ¼ .007) and a reduction of 34% in rate of
major vascular events (P ¼ .002), with no increase in bleeding. In patients
who are warfarin-adverse, aspirin after a ﬁrst event of VTE therefore
appears to provide protection against recurrent VTE and other major
vascular events.
